Climb Bio Says Single 320 mg CLYM116 Dose Suppressed APRIL Over 90%, IgA 60-75% Through 12 Weeks In Phase 1 Healthy Volunteers; Sees Phase 2 IgA Nephropathy Data H1 2027
Share
Why It Matters
Climb Bio's new medicine worked well in early tests, making certain proteins in healthy people's bodies smaller for three months. When a company's medicine shows it might work, people watch to see if it keeps working when real patients use it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.